I'd love to see some prelim data. If it turns out to be fantastic, my numbers are too low and then Inovio may not partner this one. So I'm probably wrong--probably too early to partner such a promising vaccine.
This would be an interesting debate actually. So what data is your statement based on? I personally believe the flu vaccine is one of their weakest vaccines, based on data from 2012-13'ish. I haven't seen anything new. I've been frank about my stance for years.
So...I'm just wondering what the pump is? I didn't see one. This isn't a known news-based move but I'm enjoying it.
Very simple thing: Premarket was down like 130 points and markets have been extremely volatile this week putting traders on edge. Some traders may have wanted to get out in anticipation of a down day. The trouble is that premarket is generally irrelevant in the absence of some big news event release. We didn't have that today. I stopped paying attention to extended hours trading unless i plan on making a purchase/sale.
I agree with stillinshock. The upfront payment is nominal. Advaxis has not read out yet. All Medi wants is an effective and safe treatment option. We have no guarantees certainly but I like the combo tx mechanistic:ally (3112 + checkpoint).
First PR only released mice results. This extended to NHP and announced the publication. Given the animal rule situation, this is significant.
They would just require a p1 safety study which is set to start in q4. If safety and reasonable immunogenicity is shown, I believe they can apply for approval which would be possible by year end 2016 or early 2017
Read about it if you'd like. This vaccine is immediately pertinent and has a market now.
I learned this may be approvable under the animal rule: efficacy in animal models and safety in humans. We may have some products very quickly.